Trial · NCT00983658
A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
NCT00983658, Phase 2, Completed, Genentech, Inc.
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma. Trials, record NCT00983658. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00983658
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
- NCT number
- NCT00983658
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 29 participants, actual
- Lead sponsor
- Genentech, Inc.
- Conditions
- Asthma
- Interventions
- huMAb OX40L, placebo
- First posted
- 2009-09-24
- Last updated
- 2026-05-28
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The primary outcome measure is the late asthmatic response (LAR) in patients treated with huMAb OX40L versus placebo | 16 weeks after the first dose | |
| Secondary | LAR after the allergen challenge in patients treated with huMAb OX40L versus placebo | Approximately Day 56 prior to third dose | |
| Secondary | Change in methacholine challenge response relative to the pre-allergen challenge PC20 | 24 hours after each allergen challenge | |
| Secondary | Early asthmatic response (EAR) in patients treated with huMAb OX40L versus placebo | Between 0 and 2 hours after each allergen challenge | |
| Secondary | Incidence and nature of treatment-emergent adverse events | Through study completion or early study discontinuation | |
| Secondary | Incidence and nature of infusion reactions | Through study completion or early study discontinuation | |
| Secondary | Incidence of infectious complications | Through study completion or early study discontinuation | |
| Secondary | Incidence, nature, relatedness, and severity of adverse events | Through study completion or early study discontinuation | |
| Secondary | Clinically significant changes in vital signs, electrocardiograms, FEV1, and safety laboratory measures | Through study completion or early study discontinuation | |
| Secondary | Incidence of anti-therapeutic antibodies | Through study completion or early study discontinuation |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 24224471 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00983658
GET https://conductscience.org/api/trials/v1/NCT00983658/registered